Jade Williams, Author at European Medical Journal - Page 4 of 22

Chiesi’s Enrico Piccinini on driving action for Rare Disease Day

Find out what the Senior Vice President, EU & International, Rare Diseases, Chiesi Group, thinks the pharma industry should consider on Rare Disease Day.

HBA CEO Mary Stutts

The HBA’s Mary Stutts on tackling bias for better women’s health

Mary Stutts, CEO, HBA, unpacks the key findings of a report exposing critical gaps in doctors’ understanding of women’s health.

The world

EMA grants accelerated review to Gilead’s PrEP drug

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.

Donal Brennan

Onc Now: Episode 11: The Obesity Cancer Connection

Donal Brennan shares insights on ovarian cancer surgery, obesity-related carcinogenesis, and innovations in patient care.

Data

ABPI urges NHS to improve data access for pharma research

A new cross-industry report is calling for the UK’s NHS to design its health data infrastructure to meet the needs of pharma researchers.

Jade Williams and Isabel O'Brien, EMJ GOLD

Does interactivity boost memory, recall and retention?

Explore the science behind memory, recall and retention, and uncover why interactive content could be the future in this podcast.

Britain

ABPI reveals data on UK’s life sciences competitive edge

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK pharma space.

Frederik-Schjesvold

Hema Now: Episode 10: Shaping the Future of Myeloma

Fredrik Schjesvold, Head of the Oslo Myeloma Center, Oslo University Hospital, and Head of the Norwegian myeloma association joins the show.

Martin Price, J&J

J&J’s Martin Price on World Cancer Day 2025 – Part 2

Uncover more of Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson’s thoughts on the oncology space

Lungs

Qureight and Avalyn unite to advance pulmonary fibrosis treatment

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive pulmonary fibrosis.